Since then, several nanobodies have been under clinical trials for cancer treatment: anti-HER2 5F7 nanobody, ALX-0141 (target nuclear factor kappa B ligand), DR5Nb1 (target DR5), and ALX-0651 (target CXCR4) [95]. Here, ERBB2 is linked to cancer.